Nuvation Bio Inc.
NUVB Healthcare Biotechnology
Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024. In the quarter to June 2026, revenue grew 555.6%, EPS fell 5.88%, free cash flow grew 10.6% and total debt rose 372.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow NUVB
Nuvation Bio Inc. (NUVB) P/E ratio
Nuvation Bio Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OCUL Ocular Therapeutix, Inc. compare | n/m |
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| STOK Stoke Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. compare | n/m |
| SEPN Septerna, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| NUVB Nuvation Bio Inc. | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)